MetaCap

Ginkgo Bioworks (DNA) vs Fennec Pharmaceuticals (FENC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals (FENC) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 66.1% versus a loss of 8.7%. Over five years, FENC leads with a +35.8% price change compared with -98.5% for DNA. Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $462.1 million), about 1.0 times the size, while Fennec Pharmaceuticals is growing revenue faster (-6.1% vs -25.1%).

Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -183.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNA-8.69%FENC+66.12%
+89%+25%-39%
Nov 21, 20251 yearNov 20, 2026
DNA-98.61%FENC+33.23%
+40%-33%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNA versus FENC key metrics
MetricDNAFENC
Share price$7.46$13.09
Market cap$483.54M$462.14M
1-day change-9.02%-2.68%
YTD return-10.23%+70.00%
1-year return-8.69%+66.12%
5-year return-98.45%+35.79%
P/E ratio (TTM)—436.33
Forward P/E—12.47
EPS (TTM)$-4.24$0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.16M$44.64M
Revenue growth (YoY)-25.06%-6.09%
Net income (latest FY)$-312.76M$-9.74M
Operating margin-185.29%-14.07%
Net margin-183.81%-21.82%
52-week high$18.22$13.85
52-week low$5.37$5.65
Distance from 52-week high-59.06%-5.49%
Analyst consensusunderperformstrong_buy
Avg. price target upside+7.24%+34.45%
Average volume2.53M220.87K
Shares outstanding53.94M35.31M
Employees48535
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FENC has outperformed DNA by 74.8 percentage points over the past year.
  • Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -183.8 cents for Ginkgo Bioworks.
  • Fennec Pharmaceuticals grew revenue faster in its latest fiscal year (-6.09% vs -25.06%).

About Ginkgo Bioworks

DNA stock →

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

DNA vs FENC FAQ

Which is bigger, Ginkgo Bioworks or Fennec Pharmaceuticals?

Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $462.14M for Fennec Pharmaceuticals (FENC).

Which stock has performed better over the past year, DNA or FENC?

FENC returned +66.12% over the past 12 months, compared with -8.69% for DNA (price return, excluding dividends). Past performance does not predict future results.

Are Ginkgo Bioworks and Fennec Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons